SAVE MONEY ON TRAVEL DEALS

University of Manchester researchers said they focused on anti-mitotic drugs that are used extensively in the United Kingdom for breast and ovarian cancer.

Led by Dr. Stephen Taylor, the scientists noted the anti-mitotic drugs, as in all chemotherapy, produce side effects. Their goal, they said, was to reduce those side effects and test the effectiveness of new and safer drugs.

"To bypass the neurotoxicity, new anti-mitotics are being generated", Taylor said. "Early clinical studies show that these drugs do not result in significant neurotoxicity. The big question now is whether they will have anti-tumor effects. To help determine this, we need to know which types of tumors are likely to be sensitive to these new agents, and which ones are likely to be resistant.

"Basically, we just watched the cells using time-lapse microscopy", said Taylor. "This allowed us to track behavior of individual cells and determine their fate when exposed to different anti-mitotic drugs."

The researchers said they discovered variation in cell behavior is far greater than previously recognized.

The study that included graduate student Karen Gascoigne appears in the journal Cancer Cell.

 BREAKING STORIES

Test could lead to better BSE detection

Andes may hold treasure trove of metals

NASA adjusts launch dates

Power naps can increase alertness, mood

Universal flu vaccine tested on humans

World's oldest captive gorilla dead

Clues to treat brain cancer discovered

Boeing machinists call midnight strike

Wallaby attacks child in Australia

Russia warns of asteroid threat

Calif. eyes fire danger from pole wires

Dentist charged with dumping medical waste

Iranian chief calls.U.N. sanctions illegal

Samsung shows interest in SanDisk

N. Korea to delay abduction probe

Cigarettes' attraction may not nicotine

Breakfast protein may help in weight loss

Nursing mothers with MRSA can be treated

Intensive care unit can traumatize kids

Coroner: Mysterious deaths were natural